Form 4: BioMarin Director Barbara Bodem Reports Stock Grant and Disposal
SEC Form 4 Filing
Director Barbara Bodem reported the acquisition of 4,720 shares of BioMarin Pharmaceutical Inc. stock through restricted stock units and the disposal of 6,900 shares.
Summary
- On May 21, 2024, Barbara W. Bodem, a director of BioMarin Pharmaceutical Inc., reported a transaction involving the company's common stock.
- Bodem acquired 4,720 shares of common stock through the grant of restricted stock units at a price of $0.
- Simultaneously, Bodem disposed of 6,900 shares.
- Following these transactions, Bodem directly owns 6,900 shares of BioMarin Pharmaceutical Inc.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects insider trading activity, which is often scrutinized by investors.
Key Dates
| Date | Description |
|---|---|
| 05/21/2024 | Date of stock grant and disposal transaction. |
| 05/23/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.